Get started
PFIZER INCPFIZER INCPFIZER INC

PFIZER INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

PFE trade ideas

Pfizer Analysis 08.02.2022Hello Traders, welcome to this free and educational analysis. I am going to explain where I think this asset is going to go over the next few days and weeks and where I would look for trading opportunities. If you have any questions or suggestions which asset I should analyse tomorrow, please leave a comment below. I will personally reply to every single comment! If you enjoyed this analysis, I would definitely appreciate it, if you smash that like button and maybe consider following my channel. Thank you for watching and I will see you tomorrow!
NYSE:PFE
by basictradingtv
10
Pfizer - Might get worse! 😨-The reason why PFE is dropping is not the economical situation but rather the COVID situation which is getting lighter (at least in folk's mind) every day. -We got omicron but it being a light virus almost like a flu also didn't catch much attention lately. -This stock throughout the pandemic depended on negative news, whoever is chaos oriented invested in this company, but lets all agree that the better the health situation gets and less of a tragedy COVID becomes, the less attention will be on this stock. -Not to say that the company is worthless now but it wont have the hype it had for sure! -Earnings are forecasted to decline on average of 6.2% per year. OUR TARGET PRICE: $45-$50
NYSE:PFE
by caldooninvestment
2
Pfizer, and why you keep old notesI got an alert on Pfizer NYSE:PFE just now that on the 30m a Tradingview Spike Alert I had setup fired. This is following research I did over the weekend to the Support level that PFE reached in the recent down move. While doing that I found an old annotation from November 2020 earnings that informed a long term dividend investment play. It's nice to see how something has performed over the long term to remind an investor to buy and hold good companies. The company has earnings tomorrow.
NYSE:PFE
by norok
1
$PFE - Downtrend Reversal - 4 Day Inside Bar - Upcoming CatalystNYSE:PFE A hammer signaled reversal for $PFE. Shortly after price broke out of the downtrend resistance. Four inside bars have formed during period of consolidation. $PFE looks primed for sharp movement. Catalyst would likely be FDA / CDC approval/rejection of its Covid vaccination for children, expected in 4th week of Feb. Application is for 2 doses, though 3 would be required. Application and study for 3rd shot are expected to be submitted during the initial application review phase. This is one ticker to be aware of. Biased long, but willing to play both sides.
NYSE:PFELong
by TheGritz
$PFE - Possible broadening wedge breakout Looking like the stock might be in the process of breaking out of that Broadening wedge. Although there is a possibility of head and shoulder completion, I am not sure it will play out. However, there is earning coming up on Feb 8 that could decide which pattern will play out. Here is how I see it. If the price breaks above $55, the bullish case will play out and price could reach $64. But if the price breaks below $50 and more importantly $49, the bearish case will play out with potential fall to $45. But I am leaning bullish case. Bullish target 1 - $56 Bullish target 2 - $64 Risk - the price breaks down to $45 and fill the gap. ——————————————————— How to read my charts? - Matching color trend lines shows the pattern. Sometimes a chart can have multiple patterns. Each pattern will have matching color trend lines. - The yellow horizontal lines shows support and resistance areas. - Fib lines also shows support and resistance areas. - The dotted white lines shows price projection for breakout or breakdown target. Disclaimer: Do your own DD. Not an investment advice.
NYSE:PFELong
by PaperBozz
1
Pfizer | Fundamental Analysis | MUST READ | LONG 🔔Historically, Pfizer has not had much momentum when it comes to stock performance. Over the past ten years, the S&P 500 Index has outperformed this large pharmaceutical company. But now Pfizer is gaining momentum. Last year it outperformed the benchmark index - Pfizer was up 60%, while the S&P 500 was up 27%. And today's Pfizer doesn't look much like Pfizer did a few years ago. In 2020, the company completed the separation of its Upjohn business, eliminating an element that was driving down revenues. Today, Pfizer has many "best sellers," a new coronavirus drug, and a full development cycle. So is it worth investing in this drug maker in 2022? First, let's look at the company's Covid business. Pfizer is a leading supplier of vaccines in many parts of the world. In the U.S., the company has fully vaccinated more than 118 million people. But overseas, Pfizer's vaccine business is actually even bigger. The company claims that it generates 75% of its revenues from vaccine sales outside the United States. The European Union recently exercised an option to supply more Pfizer vaccines, bringing the total number of doses of Pfizer vaccines to be delivered this year to over 650 million. The full agreement, signed last spring, calls for up to 1.8 billion doses to be delivered to the region by 2023. In Pfizer's latest earnings report, the company projected vaccine revenue of $36 billion for all of 2021. But this year could turn out to be even more successful for Pfizer than last year. Here's why. Vaccine orders remain high -- but with the addition of a new coronavirus product. Late last year, Pfizer received approval for the emergency use of Paxlovid, an oral coronavirus treatment. Paxlovid is a pill that should be given at the first sign of infection. The drug's main ingredient blocks the action of an enzyme necessary for the coronavirus replication process. The U.S. has ordered 20 million courses of Paxlovid treatment, and the U.K. has ordered 2.75 million. SVB Leerink analyst Geoffrey Porges predicts that Paxlovid will generate more than $24 billion in revenue this year and $29.7 billion in vaccines, according to FiercePharma. That amounts to more than $50 billion in revenue from the coronavirus program alone. Of course, investors are most concerned about what will happen to these revenues in a post-pandemic world. Right now, it's impossible to accurately predict the level of revenue from the coronavirus program in the future. And that represents uncertainty. Nevertheless, experts say the coronavirus will exist. And that means we will need remedies and treatments. So we can probably expect a satisfactory level of revenue from coronavirus-related products for quite some time. But here's the best news: Pfizer is far from being a coronavirus-only company. The company's nine-month earnings report shows that at least six products are generating blockbuster revenue. And in the third quarter, the company says, revenue excluding the coronavirus vaccine rose 7 percent to more than $11 billion. As if that weren't enough, Pfizer has something else to like. And that's the pipeline. The company is working on 94 programs -- 29 of which are in Phase 3 and nine of which are in the registration phase. That means we may see a new batch of drugs in the not-too-distant future. This is important because the patent on some of Pfizer's drugs expires at the end of this decade. The blood-thinning drug Eliquis, for example, will lose protection in 2028. This is a standard part of life for a pharmaceutical company - and that's why it's important to have a strong product portfolio to make up for future patent expirations. Now let's look at the valuation. As mentioned earlier, Pfizer's stock price has risen slightly. But it is still trading at very reasonable levels. It trades at only 8.5 times projected earnings. In addition, Pfizer pays a solid dividend, with a yield of over 2.8%. So should you invest in Pfizer in 2022? Well, now seems like a good time to do so. The company generates billions of dollars in revenue from its coronavirus vaccine program. It has a portfolio of non-coronavirus drugs and a full cycle of late-stage research. The stock looks inexpensive -- and an investment in this major pharmaceutical player will provide you with passive income in the form of dividends. All of this is a great formula for success this year and in the years to come.
NYSE:PFELong
by FOREXN1
4
PFIZER (PFE) BUY STRATEGY TA SCENARIO IDEAI made a personal TA on NYSE:PFE using FIB retracements to define when to buy the current pullback reversal. PFE is currently in a very clear uptrend an its previous pullbacks "reversed" at aroung 50%-61.8% FIB so i think that this current pullback is going to reverse at around 50%. Before buying: Check Rsi bounceoff and SMA positionning to form a support Check if EMA's are likely to cross (strong uptrend) Dont wait to buy at exactly 50% fib level, price may reverse earlier and you miss the dip/opportunity, or you miss a lower dip at around 61.8% If price drops further down, may be a sign of a trend reversal ! !! This is not investing advice, you shouldn't (At all) follow my buy setup, this is a personal TA which may differ from yours. ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ If you enjoyed this post and agree with me, a like and a sub would be very nice : ) Stay updated for more content Have a nice Day : ) Bye! -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
NYSE:PFEShort
by xtekky
2
Pfeizer reversing. PFECOViD paranoia did great things for the pharma industry, including and especially Pfeizer. But, even then, nothing can grow forever. South Sea, East India and Pfeizer are no exceptions. The usual divergence with specific wave cycle finished. Highly, highly suspect for a reverse. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
NYSE:PFEShort
by Rykin_Capital